OBJECTIVE: To determine survival time for dogs with splenic hemangiosarcoma treated with splenectomy alone, identify potential prognostic factors, and evaluate the efficacy of adjuvant chemotherapy. DESIGN: Retrospective case series. ANIMALS: 208 dogs. PROCEDURES: Medical records were reviewed, long-term follow-up information was obtained, and survival data were analyzed statistically. RESULTS: 154 dogs were treated with surgery alone, and 54 were treated with surgery and chemotherapy. Twenty-eight dogs received conventional chemotherapy, 13 received cyclophosphamide-based metronomic chemotherapy, and 13 received both conventional and metronomic chemotherapy. Median survival time of dogs treated with splenectomy alone was 1.6 months. Clinical stage was the only prognostic factor significantly associated with survival time. When the entire follow-up period was considered, there was no significant difference in survival time between dogs treated with surgery alone and dogs treated with surgery and chemotherapy. However, during the first 4 months of follow-up, after adjusting for the effects of clinical stage, survival time was significantly prolonged among dogs receiving any type of chemotherapy (hazard ratio, 0.6) and among dogs receiving both conventional and metronomic chemotherapy (hazard ratio, 0.4). CONCLUSIONS AND CLINICAL RELEVANCE: Clinical stage was strongly associated with prognosis for dogs with splenic hemangiosarcoma. Chemotherapy was effective in prolonging survival time during the early portion of the follow-up period. Combinations of doxorubicin-based conventional protocols and cyclophosphamide-based metronomic protocols appeared to be more effective than either type of chemotherapy alone, but prolongations in survival time resulting from current protocols were modest.
OBJECTIVE: To determine survival time for dogs with splenic hemangiosarcoma treated with splenectomy alone, identify potential prognostic factors, and evaluate the efficacy of adjuvant chemotherapy. DESIGN: Retrospective case series. ANIMALS: 208 dogs. PROCEDURES: Medical records were reviewed, long-term follow-up information was obtained, and survival data were analyzed statistically. RESULTS: 154 dogs were treated with surgery alone, and 54 were treated with surgery and chemotherapy. Twenty-eight dogs received conventional chemotherapy, 13 received cyclophosphamide-based metronomic chemotherapy, and 13 received both conventional and metronomic chemotherapy. Median survival time of dogs treated with splenectomy alone was 1.6 months. Clinical stage was the only prognostic factor significantly associated with survival time. When the entire follow-up period was considered, there was no significant difference in survival time between dogs treated with surgery alone and dogs treated with surgery and chemotherapy. However, during the first 4 months of follow-up, after adjusting for the effects of clinical stage, survival time was significantly prolonged among dogs receiving any type of chemotherapy (hazard ratio, 0.6) and among dogs receiving both conventional and metronomic chemotherapy (hazard ratio, 0.4). CONCLUSIONS AND CLINICAL RELEVANCE: Clinical stage was strongly associated with prognosis for dogs with splenic hemangiosarcoma. Chemotherapy was effective in prolonging survival time during the early portion of the follow-up period. Combinations of doxorubicin-based conventional protocols and cyclophosphamide-based metronomic protocols appeared to be more effective than either type of chemotherapy alone, but prolongations in survival time resulting from current protocols were modest.
Authors: Karen Batschinski; Alessandra Nobre; Ernesto Vargas-Mendez; Marcello V Tedardi; Juliana Cirillo; Greice Cestari; Rodrigo Ubukata; Maria Lucia Z Dagli Journal: Can Vet J Date: 2018-09 Impact factor: 1.008
Authors: Matthew Breen; Jaime F Modiano; Ingegerd Elvers; Kerstin Lindblad-Toh; Kate Megquier; Jason Turner-Maier; Ross Swofford; Jong-Hyuk Kim; Aaron L Sarver; Chao Wang; Sharadha Sakthikumar; Jeremy Johnson; Michele Koltookian; Mitzi Lewellen; Milcah C Scott; Ashley J Schulte; Luke Borst; Noriko Tonomura; Jessica Alfoldi; Corrie Painter; Rachael Thomas; Elinor K Karlsson Journal: Mol Cancer Res Date: 2019-09-30 Impact factor: 5.852
Authors: Antonella Borgatti; Ann Fieberg; Amber L Winter; Kathleen Stuebner; Elizabeth Taras; Deborah Todhunter; Alison Masyr; Aaron Rendhal; Daniel A Vallera; Joseph S Koopmeiners; Jaime F Modiano Journal: Vet Comp Oncol Date: 2020-04-02 Impact factor: 2.613
Authors: Alison R Masyr; Aaron K Rendahl; Amber L Winter; Antonella Borgatti; Jaime F Modiano Journal: J Am Vet Med Assoc Date: 2021-03-15 Impact factor: 1.936